Growth Metrics

DBV Technologies (DBVT) Liabilities and Shareholders Equity (2014 - 2026)

DBV Technologies (DBVT) reported Liabilities and Shareholders Equity of $266.4 million for Q1 2026, up 426.88% year-over-year from $50.6 million in Q1 2025, and up 13.99% on a QoQ basis from $233.7 million in Q4 2025.

DBV Technologies (DBVT) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $266.4 million in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 426.88% year-over-year to $266.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $754.0 million (up 133.11% YoY) and the FY2025 annual result came in at $233.7 million, up 255.94% from the prior year.
  • Liabilities and Shareholders Equity climbed to $266.4 million in Q1 2026 per DBVT's latest filing, from $233.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $285.0 million in Q2 2022 and bottomed at $50.6 million in Q1 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $183.0 million (2023), against an average of $173.2 million.
  • The widest annual swing landed in 2025, when Liabilities and Shareholders Equity sank 65.34%; it then surged 426.88% in 2026.
  • Tracing DBVT's Liabilities and Shareholders Equity over 5 years: stood at $246.5 million in 2022, then declined by 25.77% to $183.0 million in 2023, then plunged by 64.12% to $65.7 million in 2024, then soared by 255.94% to $233.7 million in 2025, then rose by 13.99% to $266.4 million in 2026.
  • Per Business Quant, the three latest DBVT Liabilities and Shareholders Equity figures stand at $266.4 million (Q1 2026), $233.7 million (Q4 2025), and $110.5 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 14.93 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 37.37 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 1.73 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 78.88 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 33.89 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 26.48 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 23.64 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 40.87 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 5.13 Bn
10 DBV Technologies 8.00 Bn 7.77 Bn -3.90 Mn 266.40 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 266.40 Mn
Dec 31, 2025 233.70 Mn
Sep 30, 2025 110.50 Mn
Jun 30, 2025 143.43 Mn
Mar 31, 2025 50.56 Mn
Dec 31, 2024 65.66 Mn
Sep 30, 2024 93.06 Mn
Jun 30, 2024 114.19 Mn
Mar 31, 2024 145.90 Mn
Dec 31, 2023 182.99 Mn
Sep 30, 2023 189.78 Mn
Jun 30, 2023 217.52 Mn
Mar 31, 2023 232.93 Mn
Dec 31, 2022 246.52 Mn
Sep 30, 2022 248.12 Mn
Jun 30, 2022 284.98 Mn
Mar 31, 2022 117.58 Mn
Dec 31, 2021 146.72 Mn
Sep 30, 2021 170.92 Mn
Jun 30, 2021 200.58 Mn
Mar 31, 2021 221.41 Mn
Dec 31, 2020 272.25 Mn
Jun 30, 2020 330.06 Mn
Dec 31, 2019 267.29 Mn
Sep 30, 2019 171.68 Mn
Jun 30, 2019 209.74 Mn
Dec 31, 2018 196.03 Mn
Jun 30, 2018 298.68 Mn
Dec 31, 2017 209.36 Mn
Jun 30, 2017 261.59 Mn
Dec 31, 2016 310.42 Mn
Jun 30, 2016 370.67 Mn
Dec 31, 2015 376.28 Mn
Jun 30, 2015 131.52 Mn
Dec 31, 2014 156.75 Mn